Leiden, Netherlands

Mandy Antonia Catharina Jongeneelen

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 38(Granted Patents)


Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Mandy Antonia Catharina Jongeneelen

Introduction

Mandy Antonia Catharina Jongeneelen is a prominent inventor based in Leiden, Netherlands. She has made significant contributions to the field of vaccine development, particularly focusing on influenza virus vaccines. With a total of four patents to her name, her work has the potential to impact public health positively.

Latest Patents

Jongeneelen's latest patents include innovative approaches to influenza virus vaccines. One of her notable patents involves group 2 influenza hemagglutinin stem polypeptides, which are crucial for developing effective vaccines. This patent outlines the use of nucleic acids encoding these polypeptides, vectors that incorporate the nucleic acid, and pharmaceutical compositions that utilize these components. The methods described aim to prevent and treat influenza virus infections, showcasing her commitment to advancing medical science.

Career Highlights

Throughout her career, Jongeneelen has worked with reputable organizations, including Janssen Vaccines & Prevention B.V. and Crucell Holland B.V. Her experience in these companies has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research in vaccine technology.

Collaborations

Some of her notable coworkers include Ferdinand Jacobus Milder and Tina Ritschel. Their collaborative efforts have further enhanced the research and development of innovative vaccine solutions.

Conclusion

Mandy Antonia Catharina Jongeneelen's work in the field of influenza vaccines exemplifies her dedication to innovation and public health. Her patents and collaborations reflect her significant contributions to medical science, paving the way for future advancements in vaccine development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…